Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVMZ


Primary Symbol: PAVM

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

PAVmed Provides Business Update and First Quarter 2024 Financial Results

PR Newswire 5 days ago

Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results

PR Newswire 5 days ago

Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

PR Newswire 9 days ago

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

PR Newswire 11 days ago

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

PR Newswire May 3, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

PR Newswire May 2, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

PR Newswire May 2, 2024

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

PR Newswire April 30, 2024

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

PR Newswire April 29, 2024

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire April 8, 2024

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

PR Newswire March 26, 2024

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PR Newswire March 21, 2024

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PR Newswire March 21, 2024

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

PR Newswire March 20, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

PR Newswire March 13, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

PR Newswire March 12, 2024

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

PR Newswire February 16, 2024

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

PR Newswire February 15, 2024

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

PR Newswire February 8, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

PR Newswire December 12, 2023